Genentech recently updated their trial to increase enrollments & more locations including Europe. Increasing the enrollment & adding more locations could be an indication that this drug (MPDL3280A) is getting a good objective reaponse rate
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors
Thanks James, should be an interesting trial. I’ve not heard anything definitive about this therapy. Also, GSK has a PD1 moving slowly into the pipeline. These are good trials to get into as far as I can tell. Thanks for posting!
Viewing 2 posts - 1 through 2 (of 2 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.